SCHEMBL4832572

SCHEMBL4832572

CC(C)(C)N(C(=O)OCc1ccccc1)C(Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
ITGB3 P05106 2/20 0.46
ITGA2B P08514 2/20 0.46
LMNA P02545 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
MDM4 O15151 1/20 0.42
MDM2 Q00987 1/20 0.42
ABCB1 P08183 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
CTRB1 P17538 2/20 0.40
TRPV1 Q8NER1 1/20 0.40
OPRM1 P35372 1/20 0.40
OPRD1 P41143 1/20 0.40
OPRK1 P41145 1/20 0.40
MME P08473 1/20 0.40
MIF P14174 1/20 0.39
CA12 O43570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4832582 1.00 ALDH1A1 (0.48) ALDH1A1ITGB3ITGA2BLMNACTSL
SCHEMBL9219335 0.95 ALDH1A1 (0.53) ALDH1A1ITGB3ITGA2BLMNAABCB1
SCHEMBL15876121 0.86 SLC7A5 (0.43) ALDH1A1ITGB3ITGA2BLMNAABCB1
SCHEMBL5146905 0.86 ALDH1A1 (0.51) ALDH1A1ITGB3ITGA2BLMNAABCB1
SCHEMBL31422729 0.84 ALDH1A1 (0.53) ALDH1A1ITGB3ITGA2BLMNAABCB1
SCHEMBL5421388 0.84 ALDH1A1 (0.53) ALDH1A1ITGB3ITGA2BLMNAABCB1
SCHEMBL23567069 0.83 CTSS (0.44) ITGB3ITGA2BCTSSCTSKOPRM1
SCHEMBL2957718 0.83 ALDH1A1 (0.51) ALDH1A1ITGB3ITGA2BLMNAABCB1
SCHEMBL23567068 0.83 CTSS (0.44) ITGB3ITGA2BCTSSCTSKOPRM1
SCHEMBL28620431 0.83 CTSL (0.48) ITGB3ITGA2BLMNACTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348333-B2 Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists AVENTIS PHARMA S.A. (FR) 2008-03-25 US disclosed
US-20080021055-A1 Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists AVENTIS PHARMA S.A. 2008-01-24 US disclosed
US-20030050314-A1 Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists AVENTIS PHARMA S.A. 2003-03-13 US disclosed
US-6399620-B1 (2S)-2-(1-ADAMANTYL-METHYLOXYCARBONYLAMINO)-3-(4-(3-GUANIDINO -CARBONYL-PROPYLOXY)PHENYL)PROPIONIC ACID; ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS AVENTIS PHARMA S.A. (DE) 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021055-A1 Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists ADGRF1, ADGRE5, CALCR ALDH1A1 3827/4885ITGB3 536/4885ITGA2B 379/4885
US-20030050314-A1 Novel cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists ADGRF1, CALCRL, ADGRE5 ALDH1A1 3594/4885ITGB3 545/4885ITGA2B 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.